An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

NCT02488330 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Onartuzumab
DRUG: Bevacizumab
DRUG: Erlotinib

Sponsor

Hoffmann-La Roche